Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Yuji Soejima

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5539-9280; OpenAlex author ID A5030211456, A5122270428. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 10

  1. Immunohistochemical analysis and scRNA-Seq identifies vascular endothelial CXCR4 expression as a predictor of poor prognosis in pancreatic ductal adenocarcinom… Co-author DOI 10.1016/j.tranon.2026.102916↗
  2. CXCL12 Expression and Clinicopathological Features at the Invasive Front of Pancreatic Cancer. Co-author DOI 10.1177/11795549261473797↗
  3. Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2. Last author DOI 10.1002/1878-0261.13751↗
  4. PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microenvironment in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-24-1095↗
  5. Increased mitochondria are responsible for the acquisition of gemcitabine resistance in pancreatic cancer cell lines. Last author DOI 10.1111/cas.15962↗
  6. Preoperative Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Long-Term Outcome for Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-021-10848-8↗
  7. ASO Author Reflections: Lymphocyte-to-monocyte ratio as prognostic biomarker in pancreatic ductal adenocarcinoma. Last author DOI 10.1245/s10434-021-10879-1↗
  8. Lymphoepithelial cyst mimicking pancreatic cancer: a case report and literature review. Last author DOI 10.1186/s40792-021-01191-x↗
  9. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. Co-author DOI 10.1002/cam4.1087↗
  10. Surgical Results of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: a Multi-institutional Retrospective Study of 174 patients. Co-author PMID 27127150↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kôji Kubota · 4 shared papers, 2021–2023 · strength 0.71
  2. Tadanobu Nagaya · 2 shared papers, 2026 · strength 0.49
  3. Yasuhiro Kuraishi · 2 shared papers, 2026 · strength 0.49
  4. Shunsuke Imamura · 2 shared papers, 2026 · strength 0.49
  5. Satoru Miyazaki · 2 shared papers, 2023–2025 · strength 0.42
  6. Kentaro Umemura · 2 shared papers, 2022–2025 · strength 0.33
  7. Hitoshi Masuo · 2 shared papers, 2022–2023 · strength 0.32
  8. Hiroaki Ono · 1 shared paper, 2025 · strength 0.19
  9. Daisuke Ban · 1 shared paper, 2025 · strength 0.19
  10. Yosuke Igarashi · 1 shared paper, 2025 · strength 0.19
  11. Minoru Tanabe · 1 shared paper, 2025 · strength 0.19
  12. Yoshiaki Tanji · 1 shared paper, 2025 · strength 0.19
  13. Shinji Tanaka · 1 shared paper, 2025 · strength 0.19
  14. Takuya Iguchi · 1 shared paper, 2021 · strength 0.13
  15. Toru Ikegami · 2 shared papers, 2016–2017 · strength 0.11
  16. Tomoharu Yoshizumi · 2 shared papers, 2016–2017 · strength 0.11
  17. Norifumi Harimoto · 2 shared papers, 2016–2017 · strength 0.11
  18. Shinji Itoh · 2 shared papers, 2016–2017 · strength 0.11
  19. Yoshihiko Maehara · 2 shared papers, 2016–2017 · strength 0.11
  20. Yoshinao Oda · 1 shared paper, 2017 · strength 0.06
  21. Daisuke Imai · 1 shared paper, 2017 · strength 0.06
  22. Yo Ichi Yamashita · 1 shared paper, 2016 · strength 0.05
  23. Keishi Sugimachi · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.